Damora Therapeutics Income Statement (2019-2026) | DMRA

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
8.63M9.75M10.12M13.23M13.71M10.49M10.77M10.36M8.09M2.55M2.77M2.46M1.83M1.09M1.01M0.68M1.47M1.42M23.32M23.78M
Selling, General & Administrative (Quarter)
3.63M3.19M3.35M3.70M3.41M3.13M2.75M3.13M3.07M3.30M3.18M3.28M2.77M2.75M1.70M1.92M1.96M1.74M4.07M7.03M
Other Operating Expenses (Quarter)
2.73M0.72M0.97M4.39M174.31M
Operating Expenses (Quarter)
12.27M12.94M13.47M16.94M17.12M13.62M13.53M13.49M11.16M8.58M6.67M5.74M5.58M3.84M7.10M2.60M3.42M3.16M201.70M30.81M
Operating Income (Quarter)
-12.27M-12.94M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-11.16M-8.58M-6.67M-5.74M-5.58M-3.84M-7.10M-2.60M-3.42M-3.16M-201.70M-30.81M
EBIT (Quarter)
-12.27M-12.94M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-11.16M-8.58M-6.67M-5.74M-5.58M-3.84M-7.10M-2.60M-3.42M-3.16M-201.70M-30.81M
Non-operating items
Non Operating Investment Income (Quarter)
0.02M0.03M-0.05M-0.20M-0.15M-0.08M0.18M0.09M0.03M0.06M0.06M0.03M0.00M
Other Non Operating Income (Quarter)
-0.09M0.21M0.03M-0.06M0.15M-0.33M-0.83M0.06M-0.03M-0.03M-0.21M0.01M0.07M-0.18M0.12M-0.01M-0.06M-0.02M0.00M
Non Operating Income (Quarter)
-0.03M0.24M0.06M0.00M0.23M-0.11M-0.54M0.50M0.41M0.45M0.20M0.26M0.28M-0.04M0.35M0.07M-0.01M0.02M1.00M3.07M
Net income details
EBT (Quarter)
-12.27M-12.94M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-10.74M-8.14M-6.47M-5.48M-5.30M-3.88M4.60M-2.53M-3.43M-3.13M-196.83M-27.74M
Tax Provisions (Quarter)
0.04M0.01M-0.01M0.00M0.00M0.04M0.04M
Profit After Tax (Quarter)
-12.30M-12.70M-13.41M-16.94M-16.89M-13.73M-14.07M-12.99M-10.74M-8.14M-6.47M-5.48M-5.34M-3.88M-6.74M-2.53M-3.44M-3.13M-200.74M-27.78M
Income from Continuing Operations (Quarter)
-12.27M-12.94M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-10.74M-8.14M-6.47M-5.48M-5.34M-3.88M4.60M-2.53M-3.44M-3.13M-196.88M-27.78M
Consolidated Net Income (Quarter)
-12.27M-12.94M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-10.74M-8.14M-6.47M-5.48M-5.34M-3.88M4.60M-2.53M-3.44M-3.13M-196.88M-27.78M
Income towards Parent Company (Quarter)
-12.27M-12.94M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-10.74M-8.14M-6.47M-5.48M-5.34M-3.88M4.60M-2.53M-3.44M-3.13M-196.88M-27.78M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-12.27M-12.70M-13.47M-16.94M-17.12M-13.62M-13.53M-13.49M-10.74M-8.14M-6.47M-5.48M-5.34M-3.88M4.60M-2.53M-3.44M-3.13M-196.88M-27.78M
Additional items
EPS (Basic) (Quarter)
-0.49-0.50-0.53-0.67-0.67-0.54-0.55-0.51-0.41-7.50-5.89-5.05-4.92-3.39-5.23-1.92-2.60-2.3610.86-0.62
EPS (Weighted Average and Diluted) (Quarter)
-0.50-0.53-0.67-0.67-0.54-0.55-0.51-0.41-7.50-5.89-5.05-4.92-3.39-5.23-1.92-2.60-2.3610.86-0.62
Shares Outstanding (Weighted Average) (Quarter)
25.26M25.26M25.26M25.26M25.27M25.49M25.41M25.67M26.38M1.08M1.06M1.08M1.08M1.14M1.16M1.32M1.32M1.32M1.36M34.30M
Shares Outstanding (Diluted Average) (Quarter)
25.26M25.26M25.26M25.27M25.49M25.41M25.67M26.38M1.08M1.06M1.08M1.08M1.10M1.16M1.32M1.32M1.33M1.36M34.30M
EBITDA (Quarter)
-12.13M-13.03M-13.64M-17.31M-17.69M-14.16M-12.39M-12.88M-10.75M-7.95M-6.14M-5.53M-5.47M-3.42M-7.31M-2.33M-2.93M-3.12M-200.76M-27.83M
Tax Rate (Quarter)
-0.79%-0.18%-0.17%-0.08%-0.12%-0.02%-0.15%